LONDON (Alliance News) - AstraZeneca PLC on Wednesday said it has struck a deal to acquire the core respiratory business of Japan's Takeda Pharmaceutical Co Ltd for USD575.0 million.
The FTSE 100-listed pharmaceutical giant said the deal will include an expansion to AstraZeneca's rights to roflumilast, the chronic obstructive pulmonary disease treatment. AstraZeneca has marketed the treatment, under the Daliresp name, in the US since the first quarter of 2015.
The rights also includes Daxas, the brand name for roflumilast in other territories outside the US.
"The agreement with Takeda complements our respiratory business, one of our three main therapy areas, supports our return to growth and will be immediately accretive to earnings from 2016. Daxas in particular adds to our portfolio of treatments for patients with severe COPD," said Luke Miels, executive vice-president for global portfolio and product strategy at AstraZeneca.
Some 200 staff will transfer to AstraZeneca from Takeda following completion of the deal.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)